GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCardia Inc (NAS:BCDA) » Definitions » Cyclically Adjusted Price-to-FCF

BioCardia (BioCardia) Cyclically Adjusted Price-to-FCF : (As of May. 15, 2024)


View and export this data going back to 1996. Start your Free Trial

What is BioCardia Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioCardia Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for BioCardia's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCardia Cyclically Adjusted Price-to-FCF Chart

BioCardia Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioCardia Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioCardia's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, BioCardia's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCardia's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCardia's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioCardia's Cyclically Adjusted Price-to-FCF falls into.



BioCardia Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

BioCardia's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, BioCardia's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.082/129.4194*129.4194
=-0.082

Current CPI (Dec. 2023) = 129.4194.

BioCardia Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 0.013 99.695 0.017
201406 0.037 100.560 0.048
201409 0.026 100.428 0.034
201412 0.025 99.070 0.033
201503 0.042 99.621 0.055
201506 0.042 100.684 0.054
201509 0.018 100.392 0.023
201512 0.053 99.792 0.069
201603 0.040 100.470 0.052
201606 -0.025 101.688 -0.032
201609 2.607 101.861 3.312
201612 -2.624 101.863 -3.334
201703 -0.553 102.862 -0.696
201706 -0.502 103.349 -0.629
201709 -0.421 104.136 -0.523
201712 -0.602 104.011 -0.749
201803 -0.716 105.290 -0.880
201806 -0.663 106.317 -0.807
201809 -0.474 106.507 -0.576
201812 -0.757 105.998 -0.924
201903 -0.593 107.251 -0.716
201906 -0.479 108.070 -0.574
201909 -0.247 108.329 -0.295
201912 -0.480 108.420 -0.573
202003 -0.439 108.902 -0.522
202006 -0.304 108.767 -0.362
202009 -0.287 109.815 -0.338
202012 -0.257 109.897 -0.303
202103 -0.115 111.754 -0.133
202106 -0.170 114.631 -0.192
202109 -0.156 115.734 -0.174
202112 -0.177 117.630 -0.195
202203 -0.172 121.301 -0.184
202206 -0.151 125.017 -0.156
202209 -0.113 125.227 -0.117
202212 -0.164 125.222 -0.169
202303 -0.127 127.348 -0.129
202306 -0.155 128.729 -0.156
202309 -0.112 129.860 -0.112
202312 -0.082 129.419 -0.082

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioCardia  (NAS:BCDA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


BioCardia Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of BioCardia's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCardia (BioCardia) Business Description

Industry
Traded in Other Exchanges
Address
320 Soquel Way, Sunnyvale, CA, USA, 94085
BioCardia Inc is a clinical stage regenerative medicine company. It is developing therapeutics for cardiovascular and pulmonary diseases with large unmet medical needs. The company is developing comprehensive biotherapeutic candidates for cardiac regenerative medicine namely CardiAMP and CardiALLO, with a focus on heart failure resulting from a heart attack.
Executives
Frost Phillip Md Et Al 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Bill Facteau director C/O BIOCARDIA, INC., 320 SOQUEL WAY, SUNNYVALE CA 94085
Frost Gamma Investments Trust 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137
Krisztina M Zsebo director C/O CELLADON CORPORATION, 12760 HIGH BLUFF DRIVE, SUITE 240, SAN DIEGO CA 92130
Edward M Gillis officer: Senior Vice President, Devices C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Andrew Scott Blank director C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Jim L. Allen director C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Simon H Stertzer director C/O BIOCARDIA, INC., 125 SHOREWAY DRIVE, SUITE B, SAN CARLOS CA 94070
Peter Altman director, officer: President and CEO C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
Stertzer Family Trust 10 percent owner C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
Kimberly Stertzer 10 percent owner C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
David Mcclung officer: VP of Finance C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Allan R Tessler director C/O EPOCH HOLDING CORPORATION, 640 FIFTH AVENUE, NEW YORK, NY 10019
Richard T Allen officer: VP, Quality Assurance C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Thomas Quertermous director C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070

BioCardia (BioCardia) Headlines

From GuruFocus